Published in Drug Metab Dispos on December 01, 2002
Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells. Xenobiotica (2009) 1.22
Synergistic metabolic toxicity screening using microsome/DNA electrochemiluminescent arrays and nanoreactors. Anal Chem (2008) 1.08
Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J (2009) 1.08
The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system. Genome Med (2013) 0.95
Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol (2006) 0.94
Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol (2004) 0.86
Functional characterisation of an engineered multidomain human P450 2E1 by molecular Lego. J Biol Inorg Chem (2005) 0.85
High-throughput screening assays for CYP2B6 metabolism and inhibition using fluorogenic vivid substrates. AAPS PharmSci (2003) 0.84
Significant increase in phenacetin oxidation on L382V substitution in human cytochrome P450 1A2. Drug Metab Dispos (2010) 0.83
Impact of organic solvents on cytochrome P450 probe reactions: filling the gap with (S)-Warfarin and midazolam hydroxylation. Drug Metab Dispos (2012) 0.82
P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms. Drug Metab Dispos (2015) 0.81
Monoester-Diterpene Aconitum Alkaloid Metabolism in Human Liver Microsomes: Predominant Role of CYP3A4 and CYP3A5. Evid Based Complement Alternat Med (2013) 0.81
High-Throughput Cytochrome P450 Cocktail Inhibition Assay for Assessing Drug-Drug and Drug-Botanical Interactions. Drug Metab Dispos (2015) 0.81
Effect of Hypothermia and Targeted Temperature Management on Drug Disposition and Response Following Cardiac Arrest: A Comprehensive Review of Preclinical and Clinical Investigations. Ther Hypothermia Temp Manag (2016) 0.80
Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica (2013) 0.80
Characterization of T-5 N-oxide formation as the first highly selective measure of CYP3A5 activity. Drug Metab Dispos (2013) 0.80
Linear Interaction Energy Based Prediction of Cytochrome P450 1A2 Binding Affinities with Reliability Estimation. PLoS One (2015) 0.80
Stable expression of human cytochrome P450 2D6*10 in HepG2 cells. World J Gastroenterol (2004) 0.80
Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes. Br J Clin Pharmacol (2012) 0.80
Heterologous expression of human cytochrome P450 2E1 in HepG2 cell line. World J Gastroenterol (2003) 0.80
Impact of the herbal medicine Sophora flavescens on the oral pharmacokinetics of indinavir in rats: the involvement of CYP3A and P-glycoprotein. PLoS One (2012) 0.79
Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br J Clin Pharmacol (2015) 0.78
Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine. Br J Clin Pharmacol (2010) 0.78
Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.78
Functioning of drug-metabolizing microsomal cytochrome P450s: In silico probing of proteins suggests that the distal heme 'active site' pocket plays a relatively 'passive role' in some enzyme-substrate interactions. In Silico Pharmacol (2016) 0.76
Dietary flavonoids modulate CYP2C to improve drug oral bioavailability and their qualitative/quantitative structure-activity relationship. AAPS J (2014) 0.76
Regulation of porcine hepatic cytochrome p450 - implication for boar taint. Comput Struct Biotechnol J (2014) 0.76
Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation. J Pharmacol Exp Ther (2016) 0.75
Metabolic drug-drug interaction potential of macrolactin A and 7-O-succinyl macrolactin A assessed by evaluating cytochrome P450 inhibition and induction and UDP-glucuronosyltransferase inhibition in vitro. Antimicrob Agents Chemother (2014) 0.75
Human Cytochrome P450 3A4 as a Biocatalyst: Effects of the Engineered Linker in Modulation of Coupling Efficiency in 3A4-BMR Chimeras. Front Pharmacol (2017) 0.75
Reaction temperature alters chorzoxazone metabolism in carp (Cyprinus carpio) hepatic microsomes. Fish Physiol Biochem (2012) 0.75
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol (2008) 2.23
Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics (2008) 1.72
Predicting drug-drug interactions: an FDA perspective. AAPS J (2009) 1.52
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther (2004) 1.44
Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther (2002) 1.28
Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark Med (2008) 1.20
Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol (2010) 1.18
CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet (2010) 1.12
Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm (2006) 1.11
A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol (2009) 1.10
The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther (2003) 1.10
Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol (2009) 1.05
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm Drug Dispos (2012) 1.04
Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos (2004) 1.01
Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol (2012) 1.01
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther (2005) 0.98
Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J Clin Pharmacol (2003) 0.96
Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Mol Pharm (2009) 0.94
Clinical pharmacology as a cornerstone of orphan drug development. Nat Rev Drug Discov (2011) 0.94
Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicol Appl Pharmacol (2013) 0.91
Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies. Pharmacogenomics (2004) 0.90
Qualification of biomarkers for drug development in organ transplantation. Am J Transplant (2007) 0.90
A systematic comparison of cockcroft-gault and modification of diet in renal disease equations for classification of kidney dysfunction and dosage adjustment. Ann Pharmacother (2012) 0.90
AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development. AAPS J (2011) 0.86
Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease. J Clin Pharmacol (2012) 0.86
Regulatory acceptance of toxicogenomics data. Environ Health Perspect (2004) 0.85
Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine. Biomark Med (2011) 0.85
Botanical-drug interactions: a scientific perspective. Planta Med (2012) 0.85
The role of bile salt export pump gene repression in drug-induced cholestatic liver toxicity. Drug Metab Dispos (2013) 0.83
The value meal: effect of food on lapatinib bioavailability. J Clin Oncol (2007) 0.77